First up on the podcast, producer Kevin McLean talks with staff writer Jennie Erin Smith about a new old idea for Alzheimer’s disease. They discuss how the cholinergic hypothesis originally came about, how it fell out of fashion, and why it’s making a comeback now (https://www.science.org/doi/10.1126/science.z91c7ic). Next on the show, the United States can make more power as demand goes up, but moving that increased amount of electricity around the country is proving problematic. Madeline Yozwiak (https://www.madyoz.com/), a postdoctoral scholar in the Engineering and Public Policy Department at Carnegie Mellon University, joins host Sarah Crespi to discuss her Policy Forum article on the barriers to scaling up the country’s electric grid (https://www.science.org/doi/10.1126/science.aeh4460) and some potential solutions. Finally, boosting precision medicine by looking at All of Us (https://www.science.org/doi/10.1126/scitranslmed.adt8040). The National Institutes of Health’s All of Us
First up on the podcast, people are buying consumer-grade brain wave detectors ostensibly to help with sleep, concentration, and meditation. But as freelance investigative journalist Jonathan Moens (https://jonathan-moens.com/) describes, companies are getting more than the price of the devices in the exchange (https://www.science.org/doi/10.1126/science.zp18ht9)—including training data for artificial intelligence models—in many cases without the consent of the user. Next on the show, we delve into the many uses for glucagonlike peptide-1 (GLP-1) agonist drugs beyond reducing obesity. Host Sarah Crespi talks with one of the special issue editors, Yevgeniya Nusinovich, senior editor at Science, about their potential for everything from improving cognition to combating cancer. Then we hear from Nora Volkow (https://nida.nih.gov/about-nida/directors-page/biography-dr-nora-volkow), director of the National Institute on Drug Abuse at the National Institutes of Health, about hopes for using